Comprehensive UHPLC-HR-MSE screening workflow optimized for use in routine laboratory medicine: Four workflows in one analytical method

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Comprehensive UHPLC-HR-MSE screening workflow optimized for use in routine laboratory medicine : Four workflows in one analytical method. / Mardal, Marie; Fuskevåg, Ole-Martin; Dalsgaard, Petur Weihe.

I: Journal of Pharmaceutical and Biomedical Analysis, Bind 196, 113936, 01.2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Mardal, M, Fuskevåg, O-M & Dalsgaard, PW 2021, 'Comprehensive UHPLC-HR-MSE screening workflow optimized for use in routine laboratory medicine: Four workflows in one analytical method', Journal of Pharmaceutical and Biomedical Analysis, bind 196, 113936. https://doi.org/10.1016/j.jpba.2021.113936

APA

Mardal, M., Fuskevåg, O-M., & Dalsgaard, P. W. (2021). Comprehensive UHPLC-HR-MSE screening workflow optimized for use in routine laboratory medicine: Four workflows in one analytical method. Journal of Pharmaceutical and Biomedical Analysis, 196, [113936]. https://doi.org/10.1016/j.jpba.2021.113936

Vancouver

Mardal M, Fuskevåg O-M, Dalsgaard PW. Comprehensive UHPLC-HR-MSE screening workflow optimized for use in routine laboratory medicine: Four workflows in one analytical method. Journal of Pharmaceutical and Biomedical Analysis. 2021 jan.;196. 113936. https://doi.org/10.1016/j.jpba.2021.113936

Author

Mardal, Marie ; Fuskevåg, Ole-Martin ; Dalsgaard, Petur Weihe. / Comprehensive UHPLC-HR-MSE screening workflow optimized for use in routine laboratory medicine : Four workflows in one analytical method. I: Journal of Pharmaceutical and Biomedical Analysis. 2021 ; Bind 196.

Bibtex

@article{03fd01b5d8e44db2a5b068a436fa4abe,
title = "Comprehensive UHPLC-HR-MSE screening workflow optimized for use in routine laboratory medicine: Four workflows in one analytical method",
abstract = "A comprehensive HR-MS screening can be used to identify thousands of drugs from a single analysis, which makes it a valuable tool for broad-scope component-resolved toxicological analysis. However, it is common practice in clinical toxicology to perform restricted data analysis to avoid examining and/or reporting data not requested for examination. In this study, a HR-MS screening workflow was developed to allow a comprehensive toxicological evaluation, but also restricted and levelled data analysis to fit in a clinical setting. Following precipitation and reconstitution, samples were injected on an UHPLC-HR-MS and data were analyzed with the data processing software UNIFI. Analytical validation of 38 selected drugs of abuse (DoA), included determination of matrix effect, recovery, process efficiency, and limit of identification (LOI). The method was tested on 49 authentic samples and matrix-matched ranges of calibrators for 95 drugs. The LOI ranged from 0.3 to 1426.7 ng mL-1 for most analytes which was within expected concentration range for authentic samples with THC-COOH (>1722.0 ng mL-1) and morphine (1426.7 ng mL-1) as notable exceptions. Four individual screening workflows were developed: 1) a targeted workflow to serve as orthogonal identification of the 38 selected DOAs from another in-house method, 2) a general toxicology workflow, 3) an extended toxicology workflow including new psychoactive substances (NPS), and 4) a workflow for NPS based on the online HighResNPS library. Our study presents a comprehensive LC-HR-MS toxicology screening method optimized for laboratory medicine. The workflow allows for levelled data reviewing when requested without compromising the ability to perform full toxicological analyses.",
keywords = "Chromatography, High Pressure Liquid, Chromatography, Liquid, Laboratories, Mass Spectrometry, Substance Abuse Detection, Workflow",
author = "Marie Mardal and Ole-Martin Fuskev{\aa}g and Dalsgaard, {Petur Weihe}",
note = "Copyright {\textcopyright} 2021 Elsevier B.V. All rights reserved.",
year = "2021",
month = jan,
doi = "10.1016/j.jpba.2021.113936",
language = "English",
volume = "196",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Comprehensive UHPLC-HR-MSE screening workflow optimized for use in routine laboratory medicine

T2 - Four workflows in one analytical method

AU - Mardal, Marie

AU - Fuskevåg, Ole-Martin

AU - Dalsgaard, Petur Weihe

N1 - Copyright © 2021 Elsevier B.V. All rights reserved.

PY - 2021/1

Y1 - 2021/1

N2 - A comprehensive HR-MS screening can be used to identify thousands of drugs from a single analysis, which makes it a valuable tool for broad-scope component-resolved toxicological analysis. However, it is common practice in clinical toxicology to perform restricted data analysis to avoid examining and/or reporting data not requested for examination. In this study, a HR-MS screening workflow was developed to allow a comprehensive toxicological evaluation, but also restricted and levelled data analysis to fit in a clinical setting. Following precipitation and reconstitution, samples were injected on an UHPLC-HR-MS and data were analyzed with the data processing software UNIFI. Analytical validation of 38 selected drugs of abuse (DoA), included determination of matrix effect, recovery, process efficiency, and limit of identification (LOI). The method was tested on 49 authentic samples and matrix-matched ranges of calibrators for 95 drugs. The LOI ranged from 0.3 to 1426.7 ng mL-1 for most analytes which was within expected concentration range for authentic samples with THC-COOH (>1722.0 ng mL-1) and morphine (1426.7 ng mL-1) as notable exceptions. Four individual screening workflows were developed: 1) a targeted workflow to serve as orthogonal identification of the 38 selected DOAs from another in-house method, 2) a general toxicology workflow, 3) an extended toxicology workflow including new psychoactive substances (NPS), and 4) a workflow for NPS based on the online HighResNPS library. Our study presents a comprehensive LC-HR-MS toxicology screening method optimized for laboratory medicine. The workflow allows for levelled data reviewing when requested without compromising the ability to perform full toxicological analyses.

AB - A comprehensive HR-MS screening can be used to identify thousands of drugs from a single analysis, which makes it a valuable tool for broad-scope component-resolved toxicological analysis. However, it is common practice in clinical toxicology to perform restricted data analysis to avoid examining and/or reporting data not requested for examination. In this study, a HR-MS screening workflow was developed to allow a comprehensive toxicological evaluation, but also restricted and levelled data analysis to fit in a clinical setting. Following precipitation and reconstitution, samples were injected on an UHPLC-HR-MS and data were analyzed with the data processing software UNIFI. Analytical validation of 38 selected drugs of abuse (DoA), included determination of matrix effect, recovery, process efficiency, and limit of identification (LOI). The method was tested on 49 authentic samples and matrix-matched ranges of calibrators for 95 drugs. The LOI ranged from 0.3 to 1426.7 ng mL-1 for most analytes which was within expected concentration range for authentic samples with THC-COOH (>1722.0 ng mL-1) and morphine (1426.7 ng mL-1) as notable exceptions. Four individual screening workflows were developed: 1) a targeted workflow to serve as orthogonal identification of the 38 selected DOAs from another in-house method, 2) a general toxicology workflow, 3) an extended toxicology workflow including new psychoactive substances (NPS), and 4) a workflow for NPS based on the online HighResNPS library. Our study presents a comprehensive LC-HR-MS toxicology screening method optimized for laboratory medicine. The workflow allows for levelled data reviewing when requested without compromising the ability to perform full toxicological analyses.

KW - Chromatography, High Pressure Liquid

KW - Chromatography, Liquid

KW - Laboratories

KW - Mass Spectrometry

KW - Substance Abuse Detection

KW - Workflow

U2 - 10.1016/j.jpba.2021.113936

DO - 10.1016/j.jpba.2021.113936

M3 - Journal article

C2 - 33561772

VL - 196

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

M1 - 113936

ER -

ID: 274122291